Solventum Logo
US83444M1018
A407ZE
SOLV

Solventum

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 77,11 € (-4,68 %). La mediana es de 86,29 € (+6,66 %).

Comprar
  9
Mantener
  2
Vender
  1

Debates en la comunidad


  • Solventum sharpens medtech strategy and plans spin-off of HIS division

    Solventum announced at the Wells Fargo healthcare conference that it will focus more on medical technology and spin off its Healthcare Information Services (HIS) unit, with options including sale, spin-off or partnership. The company raised its forecast for organic growth in 2026 to 2.5–3.0% but expects a near-term margin dilution of around 400 basis points from the HIS separation. MedSurg and dental (over 80% of the business) remain the main growth drivers; about 20 new products are planned by Q1 2028, with a target of 4–5% organic growth for 2028 (ex-HIS). » Más en de.investing.com


  • Solventum reaches 52-week high at $88.21

    Solventum shares rose to a new 52-week high of $88.21, gaining nearly 11% on the week. The health‑technology company has a market capitalization of $14.92 billion and is up about 20.6% year to date. Solventum beat expectations in Q1 of fiscal 2026 with EPS of $1.48 (forecast $1.34) on organic revenue growth of 2.1%. Analysts rated the stock positively; the P/E ratio is around 9.3, which the fair‑value estimate signals as a slight overvaluation. » Más en de.investing.com


  • UBS upgrade drives Solventum stock sharply higher

    UBS upgraded Solventum from “Neutral” to “Buy” and set a $95 price target, implying roughly 18% upside. The stock rose 7.6% in morning trading and hit a daily high of $87.19, close to its 52-week high of $88.20. Earlier positive analyst notes from BTIG and KeyBanc, along with four consecutive quarters of EPS beats, underpin expectations for a strong Q2 report on Aug. 5. The rally was stock-specific while broad US indices were mostly weaker. » Más en de.investing.com


  • Trian demands cost cuts, divestments and buybacks at Solventum after spin-off

    Trian Fund Management has disclosed just under a 5% stake in Solventum and, in an open letter, demanded three value-boosting measures: reduce overhead to 3M-levels, sell non-core divisions including Health Information Systems, and prioritize share buybacks. Trian criticizes that the market capitalization of around $12 billion is far below the $25 billion expected at the spin-off and sees about $13 billion of shareholder value destroyed. The investor also condemns high executive compensation since the spin-off without corresponding returns for shareholders and says it will communicate with other large shareholders and may adjust its position. » Más en de.investing.com


  • Trian demands cost cuts, sale of non-core businesses and share buybacks at Solventum

    Trian Fund Management has disclosed an almost 5% stake in Solventum and, in an open letter, is calling for operational changes including reducing overhead to 3M levels, selling non-core divisions such as Health Information Systems, and prioritizing share buybacks. Trian criticizes Solventum for not delivering returns to shareholders since the spin-off and sees a dilution of company value compared with earlier analyst estimates. Solventum is trading near its 52-week low but remains profitable with earnings of $8.88 per share and a P/E ratio of 7.78. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Solventum tuvo unos ingresos de 1720,68 M € y un beneficio neto de -10,59 M €
(EUR) septiembre de 2026
YoY
Ingresos 1720,68 M 3,66 %
Beneficio bruto 937,59 M 6,52 %
Beneficio neto -10,59 M 100,98 %
EBITDA 50,32 M 96,57 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
13,75 mil M €
Número de acciones
169,96 M
Máximo/mínimo de 52 semanas
85,53 € - 56,66 €
Dividendos No
Beta
0,75
Ratio P/E
100,09
Ratio PEG
-1,11
Ratio P/B
3,17
Ratio P/S
1,85

Perfil de la empresa

Solventum Corporation, una empresa del sector sanitario, se dedica al desarrollo, la fabricación y la comercialización de una cartera de soluciones para atender necesidades críticas de clientes y pacientes. Opera a través de cuatro segmentos: Medsurg, Dental Solutions, Health Information Systems y Purification and Filtration. El segmento Medsurg ofrece soluciones que incluyen cuidado avanzado de heridas, gestión de sitios de I.V., garantía de esterilización, gestión de la temperatura, suministros quirúrgicos, estetoscopios y electrodos médicos. El segmento Dental Solutions proporciona un conjunto completo de productos dentales y de ortodoncia, incluidos brackets, alineadores, cementos restauradores y agentes de unión. Health Information Systems ofrece soluciones de software, incluidas herramientas asistidas por computadora, documentación médica, facturación directa y automatización de codificación, metodologías de clasificación, reconocimiento de voz y plataformas de visualización de datos. El segmento Purification and Filtration proporciona tecnologías de purificación y filtración, incluidos filtros, purificadores, cartuchos y membranas. La compañía fue constituida en 2023 y tiene su sede en Saint Paul, Minnesota.

Nombre
Solventum
CEO
Bryan C. Hanson
Sede Eagan, mn
Estados Unidos
Sitio web
Sector
Salud
Industria
Equipos y suministros sanitarios
Salida a bolsa
21/07/2014
Empleados 20.584

Símbolos bursátiles

Bolsa Símbolo
NYSE
SOLV
Frankfurt
KB7.F
Düsseldorf
KB7.DU
München
KB7.MU
🍪

Parqet  usa cookies. Más información